Domov › Burkittov limfom › Missouri › Kansas City

Klinične študije za Burkittov limfom v Kansas City, MO

10 študij za Burkittov limfom išče udeležence na lokacijah v Kansas City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

Children's Mercy Hospitals and Clinics, Kansas City

366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 3

University of Kansas Hospital-Westwood Cancer Center, Westwood · 5 mi stran

Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 2

University of Kansas Hospital-Westwood Cancer Center, Westwood · 5 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Vključevanje udeležencevFaza 2

Children's Mercy Hospitals and Clinics, Kansas City

365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Vključevanje udeležencevFaza 1/2

Children's Mercy Hospital ( Site 1024), Kansas City

6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

Children's Mercy Hospitals and Clinics, Kansas City

Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Vključevanje udeležencevFaza 3

Children's Mercy Hospitals and Clinics, Kansas City

365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Vključevanje udeležencevFaza 1/2

University of Kansas Hospital-Westwood Cancer Center, Westwood · 5 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 31. jul. 2026 · NCT07069699

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

Vključevanje udeležencevFaza 1

University of Kansas Cancer Center, Westwood · 5 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 14. maj 2026 · NCT06879340

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Vključevanje udeležencevFaza 2

Children's Mercy Hospital, Kansas City

Starost 1–25 · Vsi spoli · Posodobljeno 4. maj 2025 · NCT03509961

Študije za Burkittov limfom v drugih mestih

Druge študije v Kansas City

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.